A hip fracture signals a major increase in subsequent fracture risk and mortality, yet many patients do not receive effective secondary fracture prevention. This landmark randomized, double-blind, placebo-controlled trial evaluated yearly intravenous zoledronic acid in patients who had recently undergone surgical repair of a hip fracture. Over follow-up, zoledronic acid reduced the risk of new clinical fractures and was associated with lower all-cause mortality compared with placebo. The study was important because it showed that secondary osteoporosis treatment after hip fracture can influence not only skeletal outcomes but also broader survival. The intravenous route also provided a practical advantage for patients who may struggle with adherence to oral therapy. For clinicians, the trial supports viewing the postoperative period as an opportunity to initiate a structured fracture-prevention pathway rather than focusing solely on surgical healing. Vitamin D and calcium status, renal function, dental considerations and the timing of therapy still require attention. The broader message is that hip fracture care should extend beyond fixation or arthroplasty. Secondary prevention, fall-risk assessment, rehabilitation and osteoporosis treatment can materially change long-term risk. This trial remains a cornerstone of modern fracture liaison and post-hip-fracture osteoporosis management.